Stock·NYSE·Healthcare
IQVIA Holdings Inc. (IQV)
- Market cap
- $44.06B
- P/E
- 32.52
- Dividend yield
- None
- Street target
- $300.00median of 21 analysts
- 52-week range
- $154.50 $284.50
IQV stock forecast today
Where IQV stands today, and what CleaRank Financial AI makes of it.
IQV at a glance
IQVIA Holdings Inc. (IQV): Buy, 71/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($266.09 and $209.52).
- Earnings IQV beat estimates in 8 of its last 8 quarters, yet fell the next day after 2 of those beats.
- Insiders Insiders sold $52.6M and made no open-market purchases over the last 18 months.
- Valuation P/E of 32.5 against 31.9 for the Healthcare sector: broadly in line with peers (+2%).
Figures as of October 30, 2026.
CleaRank Financial AI
CleaRank rates IQVIA Holdings Inc. (IQV) Buy, with a model score of 71/100.
The trend lifts the score most: the price is 27.59% above its 200-day average and 0.47% above its 50-day average, and the 50-day average is 27.00% above the 200-day. The 50-day average stands at $266.09 and the 200-day at $209.52. Over the past year the price rose 23.50%.
Only on CleaRank
Figures we compute ourselves from IQV's own price, earnings and insider-filing history. Tap one to see it in context.
IQV stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $267.33 is 0.5% above the 50-day simple moving average of $266.09.Price above its 200-day average ›
The price is 27.6% above the 200-day simple moving average of $209.52.50-day average above the 200-day ›
The 50-day average ($266.09) is 27.0% above the 200-day average ($209.52), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 87% of its 52-week range, between $154.50 and $284.50.
IQV share price
Pick a period: each tab shows how far IQV has moved over it, to the last close.
Today's trading
Where IQV sits inside today's range and its 52-week range.
IQV fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/4P/E above the sector median ›
The trailing P/E of 32.52 is 1.9% above the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 2.55 is 25.1% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $1.4B on revenue of $17.3B, a net margin of 8.1%.Beat estimates in most recent reports ›
IQV beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for IQV.
As of October 30, 2026, IQV trades at $267.33, with a market value of $44.06B and a P/E ratio of 32.52.
What the numbers say
CleaRank Financial AI's reading of IQV's valuation, growth and risks.
At 32.52 times trailing earnings, IQV's P/E is 1.9% above the Healthcare sector median P/E of 31.9. The peer comparison on this page calls that P/E broadly in line with peers. On sales, the stock trades at 2.55 times, which is 25.0% below the sector median P/S of 3.4. Its market capitalisation stands at $44.1B.
Profit is earned at a net margin of 8.05% and an operating margin of 13.73%. Return on equity stands at 21.39%, above the sector median of 7.3%. Debt-to-equity of 2.40 completes the balance sheet picture.
The October 27, 2026 report beat estimates by 1.83%, with EPS of $3.34 against the $3.28 that analysts had expected. The share price responded positively, rising 2.76% in the next session.
IQV has beaten the EPS estimate in all 8 of its recent reports; even so, 2 of those 8 beats were followed by a lower share price the next session. Analysts' average EPS estimate for this fiscal year is $12.96, which would be growth of 8.7%, and $14.39 for next year (growth of 11.1%).
IQV's daily returns have a 30-day standard deviation of 1.73%, and its beta against the S&P 500 is 1.17. Over the last 18 months, insiders sold $52.6M of stock and made no open-market purchases. Insider sales are often planned in advance or made to cover taxes on vesting shares, so they carry less weight than open-market buying would.
IQV against the Healthcare sector
How IQV compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: Valuation is broadly in line with sector peers (2% difference), suggesting fair market pricing relative to industry standards.
Return vs XLV: Since May 20, 2025, IQV has gained 84.4% against a gain of 37.3% for XLV.
Performance against XLV
IQV and the Healthcare sector fund over the same days.
Revenue and earnings
How much IQV sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); IQV reported again on October 27, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 5.9% in FY2025 to $16.3B, from $15.4B a year earlier.
Profit margin: The net margin was 8.3% in FY2025, down from 8.9% the year before.
Profitable: IQV earned $1.4B in FY2025.
Earnings reality check
Did IQV beat what analysts expected, and how did the stock react?
Earnings record: IQV beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 2 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 27, 2026after close | $3.28 | $3.34 | +1.83% | +2.76% | - |
| Jul 28, 2026after close | $3.03 | $3.15 | +3.96% | +1.90% | -6.07% |
| May 5, 2026after close | $2.82 | $2.90 | +2.84% | +0.03% | -0.77% |
| Feb 5, 2026after close | $3.40 | $3.42 | +0.59% | +3.61% | -6.69% |
| Oct 28, 2025after close | $2.98 | $3.00 | +0.67% | -0.14% | -3.29% |
| Jul 22, 2025after close | $2.77 | $2.81 | +1.44% | +3.66% | +3.83% |
| May 6, 2025after close | $2.63 | $2.70 | +2.66% | +4.86% | +3.06% |
| Feb 6, 2025after close | $3.11 | $3.12 | +0.32% | -0.87% | -6.63% |
As of October 30, 2026, IQV has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on October 27, 2026, came in 1.83% above the estimate and the stock moved +2.76% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
IQV AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 49.0, in neutral territory.RSI below 50 ›
An RSI of 49.0 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of IQV
The score, the reasoning behind it, and what could move the price next.
IQVIA Holdings Inc. (IQV) is trading in an uptrend. At $267.33, the stock sits 0.47% above its 50-day average of $266.09 and 27.59% above its 200-day average of $209.52. It is also near the top of its 52-week range: the price is 6.04% below the high of $284.50 and 73.03% above the low of $154.50. With the 50-day average 27.00% above the 200-day, the moving averages point the same way as the price, supporting the uptrend.
The recent pullback sits within a longer record of gains. Over the past month the price fell 0.57%, while over the past three months it rose 13.75% and over the past year it rose 23.50%. A 14-day RSI of 49.0 places momentum in the neutral zone, and the MACD line is positive.
Earnings beat ›
The October 27, 2026 report beat the EPS estimate by 1.83%, and the share price rose 2.76% in the first session after it.
Source: Earnings report, October 27, 2026Rating reaffirmed ›
Stifel kept its Buy rating on October 14, 2026.
Source: Analyst action, Stifel, October 14, 2026
New analyst coverage ›
UBS restarted coverage at Buy on September 30, 2026.
Source: Analyst action, UBS, September 30, 2026
- The two nearest levels deserve attention: the 20-day EMA at $269.97 sits above the price, and the 50-day SMA at $266.09 sits below it.
- The 14-day RSI reads 49.0, in the neutral zone, with the MACD line positive; readings above 70 or below 30 mark stretched momentum.
- The share price rose 2.76% in the first session after the October 27, 2026 report. Across the last 8 reports, IQV beat estimates in 8 of 8.
IQV's uptrend depends on the price holding above its 50-day average at $266.09 and its 200-day average at $209.52. A close below the 50-day would be the first sign of that trend weakening. If the price pulls back, the 50-day SMA at $266.09 is the first level it would reach.
The first level the price meets on the way up is the 20-day EMA, at $269.97.
Technical indicators
Momentum and trend for IQV, from its daily closes.
As of October 30, 2026, with IQV at $267.33, its 14-day RSI is 49.0 (neutral territory), its 50-day simple moving average is $266.09 and its 200-day is $209.52.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What IQV moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, IQV's 1-year correlation of daily returns is +0.41 with S&P 500 (SPY), +0.30 with Nasdaq 100 (QQQ), +0.25 with Bitcoin (BTC) and +0.06 with gold (XAU).
IQV price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
19 of 21 analysts rate it a buy or strong buy, 2 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $300.00 is 12.2% above the price.No more buy ratings than three months ago ›
19 of 21 rate it a buy now, against 19 of 21 three months ago.
IQV Wall Street View
12-month price targets
The price, $267.33, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 14, 2026 | Stifel | Maintains | Buy |
| Oct 7, 2026 | Mizuho | Maintains | Outperform |
| Oct 7, 2026 | Barclays | Maintains | Overweight |
| Sep 30, 2026 | UBS | Reinstates | Buy |
| Sep 29, 2026 | RBC Capital | Maintains | Outperform |
| Sep 28, 2026 | Truist Securities | Reiterates | Buy |
As of October 30, 2026, 21 Wall Street analysts cover IQV: 19 rate it a buy or strong buy, 2 a hold and 0 a sell or strong sell. Their 12-month price targets range from $268.00 to $345.00. The median IQV price target is $300.00, 12.2% above the price of $267.33.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
IQV trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
IQV trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from IQV's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much IQV tends to move, against the market and on its own.
IQV price history and drawdowns
IQV's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.73% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 51.5%, from December 2021 to May 2025; the price is still 5.4% below that peak.Most 1-year holds ended higher ›
67% of 1-year holding periods in the last 10 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $37,264, against $41,607 in the S&P 500 (SPY).
IQV Drawdowns & Recovery
As of October 30, 2026, IQV's worst peak-to-trough fall over the last 10 years with dividends reinvested was -51.5% (December 2021 to May 2025); it is still 5.4% below that peak, and 67% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into IQV in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: IQV trailed the S&P 500 over this period: $37,264 against $41,607.
A $10,000 investment in IQV in October 2016 would be worth about $37,264 today with dividends reinvested, compared with about $41,607 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to IQV, and which have not.
Strongest month, July: an average of +10.76%, up in 10 of 10 years.
Weakest month, March: an average of -3.45%, up in 3 of 10 years.
This month, October: has averaged +1.30%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, IQV's strongest calendar month has been July (average +10.76%, up in 10 of 10 years) and its weakest March (average -3.45%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
IQV stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in IQV, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in IQV today could grow to about $14,112 by 2030 in the base case, with a 90th-percentile outcome near $32,325 and a 10th-percentile outcome around $6,160. Projections are statistical simulations, not guarantees.
IQV Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $377 for IQV by 2030 in the base case, from $267 today (1.4x over 4 years). The 10th-percentile path ends near $165. These are outcomes of a Monte Carlo simulation run on IQV's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $193 | $291 | $441 | |
| 2028 | $177 | $318 | $571 | |
| 2029 | $169 | $346 | $710 | |
| 2030 | $165 | $377 | $864 |
Method: a lognormal simulation of IQV's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
IQV insider trading
What the people running the company have bought and sold.
IQV insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought IQV shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 30, 2026, IQV insiders reported 11 open-market sales worth $52.6M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | James Grant Berkshire
Officer
|
Sell | 2.7K | $697.2K |
| Sep 2, 2026 | James Grant Berkshire
Officer
|
Option | 5.4K | $709.3K |
| Aug 3, 2026 | Walter. Richard Staub III
Officer
|
Sell | 5.5K | $1.3M |
| Jul 31, 2026 | Bhavik Patel
Officer
|
Sell | 1.9K | $436.4K |
| Jul 29, 2026 | Ari B Bousbib
Chief Executive Officer
|
Sell | 106.3K | $26.1M |
| Jul 29, 2026 | Eric M Sherbet
General Counsel
|
Sell | 5.0K | $1.2M |
| Jul 29, 2026 | Keriann Cherofsky
Officer
|
Sell | 558 | $136.8K |
| Jul 29, 2026 | Ari B Bousbib
Chief Executive Officer
|
Option | 156.2K | $12.2M |
| Apr 23, 2026 | Carol J Burt
Director
|
Grant | 1.6K | - |
| Apr 23, 2026 | John G Danhakl
Director
|
Grant | 1.6K | - |
| Apr 23, 2026 | Colleen A Goggins
Director
|
Grant | 1.6K | - |
| Apr 23, 2026 | John M Leonard
Director
|
Grant | 1.6K | - |
| Feb 6, 2026 | James Grant Berkshire
Officer
|
Grant | 2.7K | - |
| Feb 6, 2026 | Ari B Bousbib
Chief Executive Officer
|
Grant | 57.2K | - |
| Feb 6, 2026 | Ronald E Bruehlman
Chief Financial Officer
|
Grant | 16.3K | - |
| Feb 6, 2026 | Keriann Cherofsky
Officer
|
Grant | 1.1K | - |
| Feb 6, 2026 | Michael J. Fedock
Officer
|
Grant | 6.7K | - |
| Feb 6, 2026 | Alistair Grenfell
Officer
|
Grant | 11.8K | - |
| Feb 6, 2026 | Bernd Haas
Officer
|
Grant | 8.3K | - |
| Feb 6, 2026 | Bhavik Patel
Officer
|
Grant | 4.1K | - |
| Feb 6, 2026 | Eric M Sherbet
General Counsel
|
Grant | 6.8K | - |
| Feb 6, 2026 | Walter. Richard Staub III
Officer
|
Grant | 2.7K | - |
| Dec 18, 2025 | Ari B Bousbib
Chief Executive Officer
|
Sell | 36.6K | $8.1M |
| Dec 18, 2025 | Ari B Bousbib
Chief Executive Officer
|
Option | 50.0K | $3.0M |
| Oct 29, 2025 | Ari B Bousbib
Chief Executive Officer
|
Sell | 56.6K | $12.5M |
| Oct 29, 2025 | Eric M Sherbet
General Counsel
|
Sell | 4.0K | $878.8K |
| Oct 29, 2025 | Ari B Bousbib
Chief Executive Officer
|
Option | 77.6K | $4.6M |
| Oct 29, 2025 | Eric M Sherbet
General Counsel
|
Option | 10.0K | $1.3M |
| Jul 23, 2025 | Eric M Sherbet
General Counsel
|
Sell | 5.8K | $1.1M |
| Jul 23, 2025 | Keriann Cherofsky
Officer
|
Sell | 549 | $105.2K |
| Jul 23, 2025 | Eric M Sherbet
General Counsel
|
Option | 11.9K | $1.2M |
Source: TwelveData, from SEC Form 4 filings
IQV stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.